


SDC 1: Number of patients from each HCV genotype that achieve each efficacy endpoint and the pattern of virologic response.

	Nº (%)	RVR	EVR	ETVR	SVR
All patients	324 (100%)	75/226 (33.2%)	209/289 (72.3%)	204/318 (64.2%)	177/324 (54.6%)
HCV GT1/4	221 (68.2%)	32/153 (20.9%)	122/195 (62.5%)	115/217 (52.9%)	92/221 (41.6%)
HCV GT1	184 (56.8%)	27/123 (21.9%)	104/161 (64.6%)	98/181 (54.1%)	78/184 (42.4%)
HCV GT4	37 (11.4%)	5/30 (16.7)	18/34 (52.9%)	17/36 (47.2%)	14/37 (37.8%)
HCV GT3	103 (31.6%)	43/73 (58.9%)	87/94 (92.6%)	89/101 (88.1%)	85/103 (82.5%)

Abbreviations: RVR, rapid virologic response; EVR, early virologic response; ETVR, end-of-treatment virologic response; SVR, sustained virologic response; HCV, Hepatitis C virus.

SDC2. Pairwise linkage disequilibrium (LD) patterns for four polymorphisms through IL28B regions. Each diagonal represents a different SNP, with each square representing a pairwise comparison between two SNPs.



SNPs	D'	LOD	r^2
rs12980275/rs11881222	0.977	110.09	0.941
rs12980275/rs8099917	0.96	45.66	0.503
rs12980275/rs7248668	0.948	44.47	0.494
rs11881222/rs8099917	0.986	47.37	0.513
rs11881222/rs7248668	0.973	45.84	0.503
rs8099917/rs7248668	1.0	101.95	0.99

SCD3: Number of patients from each HCV genotype stratified by rs12980275 (a) and rs8099917 (b) that achieve each efficacy endpoint and the pattern of virologic response.

(a) rs12980275

Responders/total (%)

RVR	All patients	GT1	GT3	GT4
AG+GG	33/127 (26)	10/69 (14)	20/33 (61)	3/25 (12)
AA	42/98 (43)	17/53 (32)	23/40 (58)	2/5 (40)
EVR				
AG+GG	90/153 (59)	43/88 (49)	29/32 (91)	12/27 (44)
AA	114/132 (86)	57/70 (81)	51/55 (93)	6/7 (86)
ETVR				
AG+GG	87/170 (51)	40/100 (40)	29/35 (83)	12/29 (41)
AA	119/147 (81)	59/80 (74)	54/60 (90)	6/7 (86)
SVR				
AG+GG	73/174 (42)	31/103 (30)	27/35 (77)	3/30 (30)
AA	104/149 (70)	47/80 (59)	52/62 (84)	5/7 (71)

(b) rs8099917

Responders/total (%)

RVR	All patients	GT1	GT3	GT4
TG+GG	20/86 (23)	6/47 (13)	12/21 (57)	2/18 (11)
TT	55/140 (39)	21/76 (28)	31/52 (60)	3/12 (25)
EVR				
TG+GG	60/106 (57)	30/62 (48)	22/24 (92)	8/20 (40)
TT	145/180 (81)	71/97 (73)	64/69 (93)	10/14 (71)
ETVR				
TG+GG	54/117 (46)	24/70 (34)	21/26 (81)	9/21 (43)
TT	153/201 (76)	76/111 (68)	68/75 (91)	9/15 (60)
SVR				
TG+GG	42/120 (35)	17/73 (23)	20/26 (77)	5/21 (24)
TT	135/204 (66)	61/111 (55)	65/77 (84)	9/16 (56)

Abbreviations: RVR, rapid virologic response; EVR, early virologic response; ETVR, end-of-treatment virologic response; SVR, sustained virologic response; HCV, Hepatitis C virus.

SDC4: Hosmer and Lemeshow Goodness-of-Fit test for the regression logistic model

	RVR		EVR		ETVR		SVR	
	Chi-square	Sig.	Chi-square	Sig.	Chi-square	Sig.	Chi-square	Sig.
Overall ^(a)								
rs12980275 (AA)	9.119	0.244	4.865	0.772	6.700	0.461	8.428	0.296
rs8099917 (TT)	9.946	0.192	5.248	0.630	6.033	0.536	5.526	0.596
HCV GT1/4 ^(b)								
rs12980275 (AA)	5.959	0.814	6.538	0.257	4.361	0.359	2.435	0.656
rs8099917 (TT)	1.540	0.908	5.977	0.426	5.763	0.330	2.418	0.789
HCV GT1 ^(b)								
rs12980275 (AA)	1.827	0.768	6.647	0.355	4.305	0.506	2.458	0.652
rs8099917 (TT)	1.498	0.827	5.238	0.388	5.238	0.388	1.185	0.881
HCV GT4 ^(b)								
rs12980275 (AA)	2.134	0.711	3.153	0.533	2.211	0.697	3.646	0.456
rs8099917 (TT)	2.521	0.773	2.854	0.723	4.751	0.576	4.109	0.391

(a), These tests were adjusted by HCV-genotype 1 or 4 versus 3, HCV-RNA $\geq 500,000$ IU/mL and significant fibrosis ($F \geq 2$). .

(b), These tests were adjusted by HCV-RNA $\geq 500,000$ IU/ml and significant fibrosis ($F \geq 2$).

Abbreviations: RVR, rapid virologic response; EVR, early virologic response; ETVR, end-of-treatment virologic response; SVR, sustained virologic response; HCV, Hepatitis C virus.

SDC5. Baseline plasma values of cytokines according to rs12980275 *IL28B* genotypes and HCV genotype (HCV GT) in 57 HIV/HCV coinfecting patients.

Cytokine	GG/AG		AA		<i>IL28B</i> /HCV GT
	HCV GT1/4	HCV GT3	HCV GT1/4	HCV GT3	p-value ^(a)
	21	6	14	15	
IFN- γ	7.34 (4.47 - 9.67)	7.35 (3.34 - 9.72)	4.69 (3.05 - 7.08)	4.07 (1.85 - 6.41)	0.006
IL-5	17.48 (11.57 - 22.37)	21.07 (10.86 - 32.07)	9.57 (6.41 - 16.36)	13.94 (10.82 - 19.46)	0.989
IL-9	1.73 (1.31 - 2.46)	1.67 (0.7 - 9.82)	1.39 (0.88 - 2.09)	1.2 (0.56 - 1.62)	0.048
TNF- α	10.04 (6.67 - 11.59)	4.56 (2.05 - 7.1)	5.48 (4.15 - 13.18)	5.19 (2.49 - 10.16)	0.228
IL-6	14.88 (2.42 - 17.03)	5.76 (2.07 - 8.28)	4.52 (1.84 - 17.03)	3.68 (2.24 - 13.73)	0.599

Values are expressed as median (P25th - P75th).

Statistically significant differences are shown in bold.

Only the most relevant and significant comparisons are shown.

(a), differences among patients from opposite groups: GG/AG, HCV GT 1/4 and AA, HCV GT3.

Abbreviations: IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.

SDC 6. Baseline plasma values of cytokines according to rs12980275 *IL28B* genotypes and sustained virologic response (SVR) in 57 HIV/HCV coinfecting patients.

Cytokine	GG/AG			AA		<i>IL28B</i> /SVR	
	SVR (-)	SVR (+)	p-value ^(a)	SVR (-)	SVR (+)	p-value ^(b)	p-value ^(c)
	17	11		8	21		
IFN- γ	7.22 (4.1 - 9.1)	7.87 (5.71 - 10.34)	0.991	4.59 (2.7 - 7.35)	4.48 (2.57 - 6.37)	0.016	0.038
IL-5	17.01 (11.57 - 25.36)	19.46 (11.5 - 24.24)	0.994	10.72 (6.91 - 15.58)	13.68 (9.05 - 18.41)	0.369	0.862
IL-9	1.98 (1.48 - 2.46)	1.41 (0.69 - 2.06)	0.306	1.8 (1.17 - 2.17)	1.2 (0.62 - 1.57)	0.989	0.001
TNF- α	10.83 (6.91 - 12.43)	6.79 (2.1 - 10.04)	0.142	11.53 (5.45 - 14.59)	4.97 (2.89 - 8.9)	1.000	0.023
IL-6	15.82 (9.61 - 18.02)	2.24 (1.54 - 7.92)	0.005	9.36 (3.78 - 17.52)	2.78 (1.89 - 8.55)	0.995	0.015

Values are expressed as median (P25th - P75th).

Statistically significant differences are shown in bold.

Only the most relevant and significant comparisons are shown.

(a), differences in patients with GG or AG genotypes at rs12980275 *IL28B* according to SVR.

(b), differences in SVR(+) patients according to rs12980275 *IL28B* genotypes.

(c), differences among patients from opposite groups: GG/AG, SVR(-) vs. AA, SVR(+).

Abbreviations: IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.